Does HIV affect life expectancy in 2026?

Far less than it once did. With early diagnosis and sustained treatment, life expectancy is now close to that of people without HIV. In a study of more than 200,000 people, 40-year-olds who started treatment after 2015 had about 39 more years of life ahead (women) and 37 (men). aidsmap puts it plainly: with the right treatment and care, people living with HIV can live a normal lifespan.

How dramatically the picture changed

The contrast is the story. HIV.gov notes that in the early years of the epidemic, people diagnosed with HIV or AIDS "could expect to live only 1 to 2 years after their diagnosis," whereas today people diagnosed early who start and stay on antiretroviral therapy "can keep the virus suppressed and live a long and healthy life"^[5]. One measure of that shift: of the more than 1.1 million people living with diagnosed HIV in the U.S. in 2023, roughly 54% (597,296) were age 50 and older^[5]. An entire generation is aging, which was not the expected outcome in 1990.

The 18-cohort Antiretroviral Therapy Cohort Collaboration analysis in The Lancet HIV quantified the early gains: between 1996 and 2010, life expectancy for 20-year-olds starting ART rose by about 9 years in women and 10 years in men — roughly a decade for both sexes across Europe and North America^[2]. The authors attributed the improvement to less toxic drugs, better adherence, prophylaxis, management of comorbidity, more options after resistance, fewer drug interactions, and screening and prevention programs^[2].

The landmark numbers, cohort by cohort

Trickey et al., Lancet HIV (post-2015 data). Among 206,891 people with HIV, with 5,780 deaths recorded since 2015, estimated remaining life expectancy at age 40 was 39.0 years for women and 37.0 years for men who started ART after 2015 — versus 35.8 and 34.5 years for those starting before 2015^[1]. CD4 count at the start of follow-up dominated the outcome: women with CD4 ≥500 had 42.0 years left and men 39.2 years, while those with CD4 under 49 had 24.9 and 23.7 years^[1]. The authors' conclusion is the headline: for people on ART with high CD4 counts, life expectancy "was only a few years lower than that in the general population, irrespective of when ART was started"^[1].

Kaiser Permanente (Marcus et al.). Comparing about 39,000 adults with HIV to 387,785 matched adults without HIV between 2000 and 2016, the gap in overall life expectancy at age 21 fell from 22.1 years in 2000–2003 to 9.1 years in 2014–2016 (56.0 vs 65.1 years), and narrowed further to 6.8 years among people who started ART with a CD4 count ≥500/µL in 2011–2016^[3].

ART-CC (Europe and North America, 2008–2010 starters). People starting ART at age 20 whose CD4 exceeded 350 cells/µL one year later had an estimated life expectancy of 78.0 years — which the authors described as "approaching that of the general population"^[2]. Read alongside Trickey's 39 remaining years at age 40, both point to roughly a normal lifespan for people diagnosed early and treated consistently^[1].

What still drives the remaining gap

Three themes recur across the primary literature, and none of them is "HIV medication."

Late diagnosis. Trickey et al. emphasize the "continuing importance of early diagnosis and sustained treatment of HIV," because estimates for people with low CD4 counts at the start of follow-up were substantially lower^[1]. The earlier ART-CC paper likewise called for continued efforts to address late diagnosis and late presentation to care, and to support lifelong adherence^[2].

Comorbidities, not the drugs. ART-CC authors wrote that because modern ART is highly effective with low toxicity, remaining excess mortality "is unlikely to be addressed by further development of antiretroviral drugs" — instead, attention belongs on lifestyle factors affecting adherence, non-AIDS mortality, and the diagnosis and treatment of comorbidities^[2]. HIV.gov notes that HIV-associated non-AIDS conditions such as cardiovascular disease, diabetes, renal disease and cancer occur frequently in older people with HIV, likely related to interacting factors including chronic inflammation caused by HIV^[5].

Health equity and access. ART-CC called for interventions to promote modern therapy to vulnerable populations, such as people who inject drugs, plus improved access to opioid substitution treatment and direct-acting antivirals for hepatitis C co-infection — and noted that life expectancy was lower in North America than in Europe^[2]. aidsmap adds the broader point that social and economic circumstances, income, education and mental wellbeing shape everyone's life expectancy^[6]. These are solvable problems, not features of the virus.

Healthy years, not just years

Here is the honest caveat. In the Kaiser cohort, the gap in comorbidity-free years at age 21 did not close the way total life expectancy did: 15.3 years in 2000–2003 and 16.3 years in 2014–2016 (14.5 vs 30.9 comorbidity-free years)^[3]. Among people who started ART at CD4 ≥500/µL, that comorbidity-free gap narrowed to 9.5 years^[3] — early treatment again doing the heavy lifting.

Broken out by condition in 2011–2016, gaps in comorbidity-free life expectancy ranged from 7.4 years for diabetes to 24.5 years for chronic liver disease, with 9.0 years for cardiovascular disease. Among people who started ART at CD4 ≥500/µL, the gap shrank for every comorbidity and disappeared entirely for diabetes^[3]. This is where ordinary preventive care earns its keep: aidsmap notes that not smoking and a healthy lifestyle can increase life expectancy^[6], and HIV.gov points out that medications such as statins can be used alongside HIV treatment to help treat or prevent comorbidities^[5]. Blood pressure, cholesterol, liver health, and smoking are as much part of HIV care as the viral load.

Treatment is the whole engine — and U=U comes with it

Every one of these gains rests on getting and staying virally suppressed. CDC explains that HIV treatment can make viral load so low a test cannot detect it, and that "most people can get HIV under control within six months"^[4]. CDC is also direct about timing: all people with HIV should take treatment regardless of how long they have had HIV or how healthy they feel, because delaying lets HIV keep harming the immune system and raises the chance of getting sick and developing AIDS^[4].

The same treatment that protects your health protects your partners. CDC states that with an undetectable viral load "you will not transmit HIV through sex" — known as Undetectable = Untransmittable (U=U) — and that an undetectable viral load also prevents transmission through pregnancy, labor and delivery^[4].

Two caveats worth carrying. aidsmap notes that life expectancy figures are averages calculated by projecting current mortality rates forward, and that we still have limited experience of people living with HIV into their seventies and eighties^[6] — while also observing that future improvements in care could mean people live longer than current estimates suggest^[6]. And Trickey's estimates describe people already on ART for at least a year, not the untreated population^[1]. The number that matters most is not in any paper: it is whether you are diagnosed early, in care, and suppressed.

Related questions

Related from RiseUpToHIV